Catalent ( NYSE: CTLT ) said it is unable to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2024 by the prescribed filing due date of August 29, 2024, as the company requires additional time to complete certain processes and closing procedures. The company does not expect any material change to the financial results to be included in the Form 10-K compared to the financial information reported in the earnings release, according to a filing . Earlier on Thursday, Catalent beat Wall Street forecasts with its Q4 FY24 financials months ahead of its pending buyout transaction with Novo Holdings, the investment arm of Novo Nordisk’s ( NVO ) controlling shareholder.
The contract drug manufacturer reiterated its plans to close the $16.5B all-cash deal by the end of the 2024 calendar year. The stock closed marginally higher on Friday.
More on Catalent Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy Catalent ends FY24 on a strong note ahead of Novo buyout CDMO executive says Novo purchase of Catalent may help competition - CTFN.